Real-world observation studies have suggested that AML patients with lower copies of NPM1/mut tend to have a favorable prognosis(Döhner et al., 2017), which aligns with the favorable clinical outcomes based on our findings in higher Suppressyn groups (Figure 3). Here, NPM1 is linked to acute myeloid leukemia.